Los Angeles, CA, Dec. 19, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), announced today that its previously announced 1-for-1,000 reverse split of its common stock will become effective as of December 19, 2019. Beginning on December 20, 2019, the Company’s common stock will trade […]

Los Angeles, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), announced today it has determined to effect a 1-for-1,000 reverse stock split of the Company’s issued common shares. The reverse stock split will take effect, and the Company’s common stock will begin […]

Los Angeles, CA, Nov. 19, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), announced today its financial results for the quarter ended September 30, 2019. Key Financial Highlights: Revenues for the three months ended September 30, 2019 increased 153% to $54,039, as compared to $21,306 […]

Los Angeles, CA, Oct. 31, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) today announced that it had filed a preliminary information statement with respect to a proposed a reverse stock split of its common stock at a ratio of between 1 for 100 and […]

Los Angeles, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) today announces it has appointed Dr. William Li as Strategic Advisor to the CEO. Dr. Li and Endonovo CEO Alan Collier will work collaboratively and strategically to explore growth strategies for Endonovo’s […]

LOS ANGELES, Aug. 30, 2019 (GLOBE NEWSWIRE) — via NetworkWire — Endonovo Therapeutics Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, today announces the appointment of orthopedic surgeon Dr. Geoffrey Abrams to its scientific advisory board. “We are thrilled to announce that Dr. Abrams […]

LOS ANGELES, Aug. 13, 2019 (GLOBE NEWSWIRE) — via NetworkWire – Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announces financial and operating results for the second quarter ended June 30, 2019. Alan Collier, Endonovo’s chief executive officer, stated, “I am pleased to announce we have executed the business […]

Los Angeles, CA , May 09, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, that Roc Alan McCarthy, D.O. will be joining the company as a Scientific Advisory Board Member. Dr. McCarthy will help Endonovo continue to advance their clinical pipeline forward and contribute to the strategic […]

Los Angeles, CA, May 07, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, Steven Ford will be joining the company as Vice President of Marketing. In his position, Mr. Ford will be responsible for growing Endonovo’s pipeline of marketing, content and thought leadership strategies. Mr. Ford has […]

Los Angeles, May 03, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced veteran sales leader David Clark joined as Endonovo’s Vice President of Sales. In his new position, Mr. Clark will lead the U.S. Sales Team, distributors and strategic partners through the next phase of growth. He’ll […]